Moderna is a step closer to showing detractors that it is no moonshot stock. The biotech group on Monday said its experimental Covid-19 vaccine was 94.5 per cent effective, according to preliminary data. That makes it the second US company, after Pfizer and its German partner BioNTech, to report positive results from late-stage clinical trials.
Moderna朝著向詆毀者表明它不是成功幾率極小的股票走近了一步。這家生物技術(shù)集團(tuán)周一表示，根據(jù)初步數(shù)據(jù)，其實(shí)驗(yàn)性新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗的有效率達(dá)到94.5%。這使其成為繼輝瑞(Pfizer)及其德國(guó)合作伙伴BioNTech之后、第二家報(bào)告后期臨床試驗(yàn)積極結(jié)果的美國(guó)公司。
您已閱讀17%（502字），剩余83%（2397字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。